Pharmacokinetics, Tolerability and Safety of Favipiravir Compared to Ribavirin for the Treatment of Lassa Fever
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This exploratory, prospective, controlled, multisite, open label, randomized clinical trial
with two treatment arms aims to compare favipiravir, a new treatment candidate for Lassa
fever (LF), with the current standard of care, ribavirin.
The primary endpoints of this research are (1) the description of classical pharmacokinetic
parameters of favipiravir in comparison with ribavirin standard treatment in patients
suffering from LF and (2) the safety and tolerability of both study drugs in the investigated
regimens.